IBRX News

IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA ® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio Announces NCCN ® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA ® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

B-cell Inhibitors Market for Non-Oncology Diseases, 2026-2035 Industry Trends and Global Forecasts - Growing Prevalence of Autoimmune Disorders and Hematologic Cancers Drives Rapid Advancement

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data